Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Radiotherapy and Cisplatin Increase Immunotherapy Efficacy by Enabling Local and Systemic Intratumoral T-cell Activity.

Kroon P, Frijlink E, Iglesias-Guimarais V, Volkov A, van Buuren MM, Schumacher TN, Verheij M, Borst J, Verbrugge I.

Cancer Immunol Res. 2019 Apr;7(4):670-682. doi: 10.1158/2326-6066.CIR-18-0654. Epub 2019 Feb 19.

PMID:
30782666
2.

Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population.

Hein N, Cameron DP, Hannan KM, Nguyen NN, Fong CY, Sornkom J, Wall M, Pavy M, Cullinane C, Diesch J, Devlin JR, George AJ, Sanij E, Quin J, Poortinga G, Verbrugge I, Baker A, Drygin D, Harrison SJ, Rozario JD, Powell JA, Pitson SM, Zuber J, Johnstone RW, Dawson MA, Guthridge MA, Wei A, McArthur GA, Pearson RB, Hannan RD.

Blood. 2017 May 25;129(21):2882-2895. doi: 10.1182/blood-2016-05-718171. Epub 2017 Mar 10.

3.

Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma.

Deken MA, Gadiot J, Jordanova ES, Lacroix R, van Gool M, Kroon P, Pineda C, Geukes Foppen MH, Scolyer R, Song JY, Verbrugge I, Hoeller C, Dummer R, Haanen JB, Long GV, Blank CU.

Oncoimmunology. 2016 Oct 14;5(12):e1238557. doi: 10.1080/2162402X.2016.1238557. eCollection 2016.

4.

Dermal Delivery of Constructs Encoding Cre Recombinase to Induce Skin Tumors in PtenLoxP/LoxP;BrafCA/+ Mice.

Deken MA, Song JY, Gadiot J, Bins AD, Kroon P, Verbrugge I, Blank CU.

Int J Mol Sci. 2016 Dec 20;17(12). pii: E2149. doi: 10.3390/ijms17122149.

5.

Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy.

Swart M, Verbrugge I, Beltman JB.

Front Oncol. 2016 Nov 1;6:233. eCollection 2016. Review.

6.

Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma.

Kroon P, Gadiot J, Peeters M, Gasparini A, Deken MA, Yagita H, Verheij M, Borst J, Blank CU, Verbrugge I.

Cancer Immunol Immunother. 2016 Jun;65(6):753-63. doi: 10.1007/s00262-016-1843-4. Epub 2016 May 9.

7.

The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.

Baker A, Gregory GP, Verbrugge I, Kats L, Hilton JJ, Vidacs E, Lee EM, Lock RB, Zuber J, Shortt J, Johnstone RW.

Cancer Res. 2016 Mar 1;76(5):1158-69. doi: 10.1158/0008-5472.CAN-15-1070. Epub 2015 Dec 1.

8.

The curative outcome of radioimmunotherapy in a mouse breast cancer model relies on mTOR signaling.

Verbrugge I, Gasparini A, Haynes NM, Hagekyriakou J, Galli M, Stewart TJ, Abrams SI, Yagita H, Verheij M, Johnstone RW, Borst J, Neefjes J.

Radiat Res. 2014 Aug;182(2):219-29. doi: 10.1667/RR13511.1. Epub 2014 Jun 24. Erratum in: Radiat Res. 2014 Oct;182(4):e45.

PMID:
24960417
9.

Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors.

Bots M, Verbrugge I, Martin BP, Salmon JM, Ghisi M, Baker A, Stanley K, Shortt J, Ossenkoppele GJ, Zuber J, Rappaport AR, Atadja P, Lowe SW, Johnstone RW.

Blood. 2014 Feb 27;123(9):1341-52. doi: 10.1182/blood-2013-03-488114. Epub 2014 Jan 10.

10.

Ubiquitination by the membrane-associated RING-CH-8 (MARCH-8) ligase controls steady-state cell surface expression of tumor necrosis factor-related apoptosis inducing ligand (TRAIL) receptor 1.

van de Kooij B, Verbrugge I, de Vries E, Gijsen M, Montserrat V, Maas C, Neefjes J, Borst J.

J Biol Chem. 2013 Mar 1;288(9):6617-28. doi: 10.1074/jbc.M112.448209. Epub 2013 Jan 8.

11.

Enhancing the antitumor effects of radiotherapy with combinations of immunostimulatory antibodies.

Verbrugge I, Galli M, Smyth MJ, Johnstone RW, Haynes NM.

Oncoimmunology. 2012 Dec 1;1(9):1629-1631.

12.

Regulating the TRAIL of destruction: how A20 protects glioblastomas from TRAIL-mediated death.

Verbrugge I, Johnstone RW.

Cancer Discov. 2012 Feb;2(2):112-4. doi: 10.1158/2159-8290.CD-11-0350.

13.

Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies.

Verbrugge I, Hagekyriakou J, Sharp LL, Galli M, West A, McLaughlin NM, Duret H, Yagita H, Johnstone RW, Smyth MJ, Haynes NM.

Cancer Res. 2012 Jul 1;72(13):3163-74. doi: 10.1158/0008-5472.CAN-12-0210. Epub 2012 May 8.

14.

Promises and challenges of anticancer drugs that target the epigenome.

Verbrugge I, Johnstone RW, Bots M.

Epigenomics. 2011 Oct;3(5):547-65. doi: 10.2217/epi.11.82. Review.

PMID:
22126246
15.

SnapShot: Extrinsic apoptosis pathways.

Verbrugge I, Johnstone RW, Smyth MJ.

Cell. 2010 Dec 23;143(7):1192, 1192.e1-2. doi: 10.1016/j.cell.2010.12.004. No abstract available.

16.

Smac/DIABLO release from mitochondria and XIAP inhibition are essential to limit clonogenicity of Type I tumor cells after TRAIL receptor stimulation.

Maas C, Verbrugge I, de Vries E, Savich G, van de Kooij LW, Tait SW, Borst J.

Cell Death Differ. 2010 Oct;17(10):1613-23. doi: 10.1038/cdd.2010.39. Epub 2010 Apr 16.

17.

Radiation and anticancer drugs can facilitate mitochondrial bypass by CD95/Fas via c-FLIP downregulation.

Verbrugge I, Maas C, Heijkoop M, Verheij M, Borst J.

Cell Death Differ. 2010 Mar;17(3):551-61. doi: 10.1038/cdd.2009.141. Epub 2009 Oct 2.

18.

Combining radiotherapy with APO010 in cancer treatment.

Verbrugge I, Wissink EH, Rooswinkel RW, Jongsma J, Beltraminelli N, Dupuis M, Borst J, Verheij M.

Clin Cancer Res. 2009 Mar 15;15(6):2031-8. doi: 10.1158/1078-0432.CCR-08-2125. Epub 2009 Mar 10.

19.

Stem cell-derived cardiomyocytes after bone marrow and heart transplantation.

de Weger RA, Verbrugge I, Bruggink AH, van Oosterhout MM, de Souza Y, van Wichen DF, Gmelig-Meyling FH, de Jonge N, Verdonck LF.

Bone Marrow Transplant. 2008 Mar;41(6):563-9. Epub 2007 Nov 26.

PMID:
18037937
20.

Ionizing radiation modulates the TRAIL death-inducing signaling complex, allowing bypass of the mitochondrial apoptosis pathway.

Verbrugge I, de Vries E, Tait SW, Wissink EH, Walczak H, Verheij M, Borst J.

Oncogene. 2008 Jan 24;27(5):574-84. Epub 2007 Aug 6.

PMID:
17684487
21.

TRAIL enhances efficacy of radiotherapy in a p53 mutant, Bcl-2 overexpressing lymphoid malignancy.

Wissink EH, Verbrugge I, Vink SR, Schader MB, Schaefer U, Walczak H, Borst J, Verheij M.

Radiother Oncol. 2006 Aug;80(2):214-22. Epub 2006 Aug 17.

PMID:
16916556

Supplemental Content

Loading ...
Support Center